Library / Peptides / Hormone Optimization / Tesamorelin

Strong evidence · Grade A

Tesamorelin

Tesamorelin (Egrifta)

Score

85 / 100

Class

Hormone Optimization

Brand

Egrifta

FDA

2010

TL;DR

Tesamorelin is an FDA-approved prescription peptide that tells your pituitary gland to make more growth hormone in a natural, pulsatile way. It was approved specifically to reduce dangerous belly fat buildup in HIV patients. Research also suggests it may help with brain function in older adults. Because it raises growth hormone and IGF-1, it requires medical supervision and monitoring.

Part 01 · How it works

Mechanism.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that is FDA-approved for the treatment of HIV-associated lipodystrophy (excess abdominal fat accumulation in HIV+ patients on antiretroviral therapy). It stimulates the pituitary to produce growth hormone in a physiologic, pulsatile manner, and has been extensively studied for visceral fat reduction, cognitive effects in older adults, and metabolic improvements.

Rather than injecting growth hormone directly — which is like flooding a room with water — tesamorelin is like turning on the faucet that your own body controls. Your brain still regulates how much flows and when, keeping things more natural and balanced.

Mechanism · technical

Tesamorelin binds to GHRH receptors in the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone (GH). This preserves the physiologic feedback regulation of the GH/IGF-1 axis, unlike exogenous GH administration. Elevated GH drives lipolysis preferentially in visceral adipose tissue, reduces trunk fat accumulation, and modestly improves lipid profiles. IGF-1 levels rise proportionally.

Part 02 · Dosing & administration

How it's taken.

Values below describe how Tesamorelin has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose

2 mg

Subcutaneous injection · Once daily

Duration

Ongoing per FDA labeling

FDA-approved (Egrifta SV) for HIV-associated lipodystrophy to reduce visceral adipose tissue. GHRH analogue. Contraindicated with active malignancy, pituitary pathology, pregnancy. Off-label use for general body composition.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator

Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects

Injection site reactions, fluid retention, arthralgia, myalgia, and peripheral edema are most common. May worsen glucose tolerance and insulin resistance. Contraindicated in active malignancy, pituitary tumor, pregnancy. Potential to increase IGF-1 above normal range with chronic use.

Absolute · do not use

Active malignancy (FDA contraindication — tesamorelin stimulates GH which can promote tumor growth)

Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor/surgery (FDA contraindication)

Pregnancy (FDA contraindication — Category X)

Known hypersensitivity to tesamorelin or mannitol (FDA contraindication)

Breastfeeding

Interactions

Insulin

Per FDA label: tesamorelin may increase insulin resistance; monitor glucose and adjust insulin dose as needed

Major

Oral hypoglycemics

GH elevation may counteract glucose-lowering effects; per FDA label, monitor blood glucose

Moderate

Corticosteroids (prednisone, hydrocortisone)

Per FDA label: glucocorticoids inhibit GH secretion and may reduce tesamorelin efficacy; 11beta-HSD1 activity altered by GH

Moderate

Cortisone acetate and prednisone (specifically)

Per FDA label: tesamorelin may reduce conversion of cortisone to cortisol and prednisone to prednisolone; patients on replacement therapy may need dose adjustment

Moderate

Labs to monitor

IGF-1

Baseline and every 3 months

Monitor growth hormone axis stimulation

Fasting Glucose & Insulin

Baseline and every 3 months

GH can impair insulin sensitivity

HbA1c

Baseline and every 3 months

FDA labeling notes glucose monitoring

CMP (Comprehensive Metabolic Panel)

Baseline and every 3 months

Liver function (studied in MASH/NAFLD)

Lipid Panel

Baseline and every 3 months

Monitor lipid changes

Visceral Fat Assessment (CT or DEXA)

Baseline and every 6 months

Primary efficacy endpoint

Part 04 · Evidence

How strong is the evidence?

Scores derived from rating, indexed studies, regulatory status, and catalogued safety data for this peptide. Curated per-peptide scoring replaces this when available.

Grade A

Grade A. Evidence is strongest where indications match regulatory approval — pair with a clinician when applying beyond label.

Clinical efficacy

Rating reflects consistent peer-reviewed evidence in its indication.

Study quality

4 indexed studies in our dataset. Designs vary — see Research log for per-study grades.

Regulatory clarity

FDA-approved for at least one indication.

Safety profile

Based on 5 documented contraindications, 4 interactions, 6 lab checkpoints.

Long-term data

Years of post-approval surveillance available.

Part 05 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

2010

Tesamorelin reduces visceral adiposity in HIV-infected patients: phase III RCT

Two pivotal phase III RCTs demonstrated that tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by approximately 15–18% from baseline over 26 weeks versus placebo in HIV lipodystrophy.

Industry-sponsored (Theratechnologies). Population-specific (HIV+ on ART). Findings may not generalize to non-HIV patients.

PMID 20660403 ↗

2019

Tesamorelin and cognitive function in older adults with mild cognitive impairment: an RCT

Tesamorelin 1 mg/day for 20 weeks improved executive function and verbal memory scores in older adults with mild cognitive impairment compared to placebo, with IGF-1 elevation correlating with cognitive benefit.

Single-site RCT, modest sample size (n=152), short duration. Cognitive endpoints were secondary in some analyses.

PMID 30615963 ↗

2019

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV

Tesamorelin significantly reduced liver fat content (measured by MRS) and improved liver enzymes in HIV-infected adults with NAFLD over 12 months.

Open-label extension study, no placebo control for the liver-specific outcomes. HIV-specific population.

PMID 30753463 ↗

2011

Long-term safety of tesamorelin in HIV lipodystrophy: 52-week extension data

Extended use demonstrated sustained VAT reduction with no significant increase in malignancy, diabetes incidence, or pituitary abnormalities over 52 weeks.

Extension study with no placebo arm. Adverse event capture may be incomplete in extension designs.

PMID 21346066 ↗

Part 06 · Cost & access

Where you can get it.

Regulatory status

FDA-approved (2010) for treatment of excess abdominal fat in HIV-infected adults with lipodystrophy (Egrifta, Egrifta SV). Off-label use for body composition and cognitive purposes is not approved. Prescription-only.

The Peptide Column takes no affiliate commission from any source.

Part 07 · Your appointment

Questions to bring.

Do I meet criteria for FDA-approved tesamorelin use (HIV-associated lipodystrophy), or would this be off-label?

What are the risks of elevating IGF-1 levels, particularly given any personal or family history of cancer?

How does tesamorelin differ from exogenous growth hormone in terms of safety?

Should my IGF-1 and glucose levels be monitored during treatment?